{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:48:59Z","timestamp":1791946139780,"version":"4.3.4"},"reference-count":58,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients included in this study were required to have archived plasma, bone marrow biopsy, and cytogenetic information available at the time of first referral to the Mayo Clinic. Multiplex biometric sandwich immunoassay was used to measure plasma levels of 30 cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 127 PMF patients were studied; comparison with normal controls (n = 35) revealed significantly increased interleukin-1\u03b2 (IL-1\u03b2), IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, tumor necrosis factor \u03b1 (TNF-\u03b1), granulocyte colony-stimulating factor (G-CSF), interferon alfa (IFN-\u03b1), macrophage inflammatory protein 1\u03b1 (MIP-1\u03b1), MIP-1\u03b2, hepatocyte growth factor (HGF), IFN-\u03b3\u2013inducible protein 10 (IP-10), monokine induced by IFN-\u03b3 (MIG), monocyte chemotactic protein 1 (MCP-1), and vascular endothelial growth factor (VEGF) levels and decreased IFN-\u03b3 levels. In treatment-naive patients (n = 90), increased levels of IL-8 (P &lt; .001), IL-2R (P &lt; .001), IL-12 (P &lt; .001), IL-15 (P = .001), and IP-10 (P = .003) were independently predictive of inferior survival. A similar multivariable analysis that included all 127 study patients confirmed the prognostic value of these five cytokines, and IL-8, IL-2R, IL-12, and IL-15 remained significant when risk stratification, according to the recently revised Dynamic International Prognostic Scoring System (DIPSS plus), was added to the multivariable model. Leukemia-free survival was predicted by IL-8, which was also the only cytokine associated with \u2265 1% circulating blasts. Other cytokine-phenotype associations included increased IL-8 and constitutional symptoms; IL-2R, IL-12, and transfusion need; IL-2R, IL-8, and leukocytosis; IP-10 and thrombocytopenia; HGF, MIG, IL-1RA, and marked splenomegaly; and IL-1RA, IL-2R, IP-10, MIP-1\u03b2, and JAK2V617F. A two-cytokine (IL-8\/IL-2R) \u2013based risk categorization delineated prognostically different groups within specific DIPSS plus risk categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study signifies the presence of specific cytokine-phenotype associations in PMF and a prognostically relevant plasma cytokine signature that might prove useful as a laboratory tool for predicting and monitoring treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2010.32.9490","type":"journal-article","created":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T22:22:29Z","timestamp":1297117349000},"page":"1356-1363","source":"Crossref","is-referenced-by-count":569,"title":["Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study"],"prefix":"10.1200","volume":"29","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"From Mayo Clinic, Rochester, MN; and Cattedra ed Unita di Ematologia con trapianto, Policlinico Universitario di Palermo, Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhee","family":"Vaidya","sequence":"additional","affiliation":[{"name":"From Mayo Clinic, Rochester, MN; and Cattedra ed Unita di Ematologia con trapianto, Policlinico Universitario di Palermo, Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Caramazza","sequence":"additional","affiliation":[{"name":"From Mayo Clinic, Rochester, MN; and Cattedra ed Unita di Ematologia con trapianto, Policlinico Universitario di Palermo, Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Finke","sequence":"additional","affiliation":[{"name":"From Mayo Clinic, Rochester, MN; and Cattedra ed Unita di Ematologia con trapianto, Policlinico Universitario di Palermo, Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra","family":"Lasho","sequence":"additional","affiliation":[{"name":"From Mayo Clinic, Rochester, MN; and Cattedra ed Unita di Ematologia con trapianto, Policlinico Universitario di Palermo, Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"From Mayo Clinic, Rochester, MN; and Cattedra ed Unita di Ematologia con trapianto, Policlinico Universitario di Palermo, Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.69"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9316"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405097"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"B8","doi-asserted-by":"crossref","unstructured":"D Caramazza,  KH Begna,  N Gangat, etal:  Refined cytogenetic risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients Leukemia doi:10.1038\/leu.2010.234 [epub ahead of print on October 14, 2010]","DOI":"10.1038\/leu.2010.234"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-6-857"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.7.1540.1540"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04970.x"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb07952.x"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.12.4534.bloodjournal88124534"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(00)00021-3"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.292671.x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402124"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830350302"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.4.2271"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.4631004.x"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V59.5.1046.bloodjournal5951046"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb01332.x"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064626"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03874.x"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3293146.x"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1342"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0193"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1133"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4843288.x"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2839"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3977"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.021"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/89.1.69"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04829.x"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1010"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04118.x"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0812"},{"key":"B37","first-page":"5996","volume":"9","author":"Ren Y","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04420-2"},{"key":"B39","first-page":"1445","volume":"6","author":"Wang LS","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404497"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn677"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03400.x"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1007-7"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6842"},{"key":"B45","volume-title":"Presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology","author":"Ansell SM"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4843"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4415"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.255"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2008.07.003"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/13547500701674063"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05674.x"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.02.012"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7356"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21827"},{"key":"B57","volume-title":"Presented at the 50th Annual Meeting of the American Society of Hematology","author":"Tefferi A"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2010.32.9490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:49:13Z","timestamp":1653508153000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.32.9490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,1]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,4,1]]}},"alternative-id":["10.1200\/JCO.2010.32.9490"],"URL":"https:\/\/doi.org\/10.1200\/jco.2010.32.9490","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.10476956.793516228","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.10476956.11315055","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,1]]}}}